NCT06543537 Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
| NCT ID | NCT06543537 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 112 participants |
| Start Date | 2025-01-17 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 112 participants in total. It began in 2025-01-17 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)
Eligibility Criteria
Participant Inclusion Criteria: * At least 18 years old * Able to speak, understand, and respond to questions written in English * Willing to be audio recorded * Have a diagnosis of advanced ovarian cancer (defined as stage III, stage IV, or recurrent disease) * Be under the care of a participating clinician dyad * Be scheduled for chemotherapy during the recruitment period * Be signed up or willing to sign up for Patient Gateway Caregiver Inclusion Criteria: * At least 18 years old * Able to speak, understand, and respond to questions written in English * Willing to be audio recorded * Be a family member, partner, or friend of a patient participant with whom the patient participant discusses their cancer care Clinician Inclusion Criteria: * Be employed at DFCI as an oncologist, nurse practitioner, or physician assistant * Take care of at least 4 patients per month with advanced ovarian cancer (defined as stage III, stage IV, or recurrent disease) in the outpatient setting Participant Exclusion Criteria: * Age of \<18 years * Unable to consent
Contact & Investigator
Rachel Pozzar, PhD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06543537 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06543537 currently recruiting?
Yes, NCT06543537 is actively recruiting participants. Contact the research team at Rachel_Pozzar@DFCI.HARVARD.EDU for enrollment information.
Where is the NCT06543537 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06543537 clinical trial?
NCT06543537 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Rachel Pozzar, PhD at Dana-Farber Cancer Institute. The trial plans to enroll 112 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.